COTQ.F Stock Overview
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cotinga Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.0001 |
| 52 Week High | CA$0.0001 |
| 52 Week Low | CA$0.0001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.75% |
| 5 Year Change | -99.98% |
| Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| COTQ.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -5.0% | -3.5% |
| 1Y | n/a | -1.7% | 20.2% |
Return vs Industry: Insufficient data to determine how COTQ.F performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how COTQ.F performed against the US Market.
Price Volatility
| COTQ.F volatility | |
|---|---|
| COTQ.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COTQ.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine COTQ.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Alison Silva | www.cotingapharma.com |
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company’s lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions.
Cotinga Pharmaceuticals Inc. Fundamentals Summary
| COTQ.F fundamental statistics | |
|---|---|
| Market cap | US$576.63k |
| Earnings (TTM) | -US$2.54m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs COTQ.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COTQ.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$608.96k |
| Gross Profit | -CA$608.96k |
| Other Expenses | CA$1.93m |
| Earnings | -CA$2.54m |
Last Reported Earnings
Jan 31, 2020
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did COTQ.F perform over the long term?
See historical performance and comparison